Payer coverage principles for precision medicine biomarker testing in oncology

Area of Science:

• Oncology
• Genomics
• Health Policy

Background:

• Precision medicine in oncology relies on biomarker testing for personalized treatment plans.
• Challenges in biomarker testing coverage impede patient access to tailored cancer therapies.
• Managed care stakeholders face difficulties in assessing and determining coverage for these tests.

Purpose of the Study:

• To collaboratively develop a standardized approach for assessing and determining coverage of biomarker testing.
• To address fundamental coverage challenges impacting patient access to precision medicine in oncology.
• To provide guiding principles for managed care stakeholders regarding biomarker testing coverage.

Main Methods:

• Convened a 2-day partnership forum involving diverse stakeholders including patients, payers, providers, and advocacy groups.
• Focused on ideating deliverables to standardize the assessment and coverage determination process for biomarker testing.
• Developed 8 guiding principles for managed care decision-makers.

Main Results:

• A critical deliverable was the creation of 8 guiding principles for managed care stakeholders.
• These principles are intended to guide decision-making on coverage for biomarker-driven testing in oncology.
• The initiative aims to drive a standardized approach to biomarker testing coverage.

Conclusions:

• Standardized coverage principles are crucial for advancing patient access to precision medicine in oncology.
• Collaboration among stakeholders is essential to overcome biomarker testing coverage challenges.
• The 8 guiding principles offer a framework for managed care organizations to determine and monitor biomarker testing coverage effectively.